share_log

HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $20 Price Target

HC Wainwright & Co.重申買入Acrivon Therapeutics,維持20美元的目標股價
Benzinga ·  04/25 07:29

HC Wainwright & Co. analyst Emily Bodnar reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and maintains $20 price target.

HC Wainwright & Co. 分析師艾米麗·博德納爾重申Acrivon Therapeutics(納斯達克股票代碼:ACRV)的買入並維持20美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論